Oral Milk-Derived Extracellular Vesicles: A Promising Drug Delivery System for Neuroinflammatory Diseases
ACS Biomaterials Science & Engineering · 2026
DOI: 10.1021/acsbiomaterials.6c00969 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Biomaterials Science & Engineering, 2026. Verfasst von Ming-Yue Bao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Medicinal Resources and Natural Pharmaceutical Chemistry (Shaanxi Normal University), The Ministry of Education; College of Life Sc…. Hauptthemen laut MEDLINE: Encephalomyelitis, Autoimmune, Experimental, Drug Delivery Systems, Extracellular Vesicles, Ellagic Acid. Die Arbeit nennt 51 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, Shanxi Provincial Science and Technology Department.
Abstract (Originalsprache)
Oral drug delivery is the most patient-friendly and safest approach for disease treatment; however, the bioavailability of macromolecular drugs and poorly soluble small molecules is severely limited by gastrointestinal degradation and the blood−brain barrier (BBB). Here, we developed a cost-effective, chitosan-based isolation method to efficiently isolate milk-derived extracellular vesicles (mEVs), which exhibit good stability in the gastrointestinal tract and intrinsic BBB-penetrating capability. Biodistribution studies showed that mEVs were absorbed in both healthy and experimental autoimmune encephalomyelitis (EAE) mice, with increased CNS accumulation under neuroinflammation, especially in oligodendrocytes and neurons. To address the poor stability and bioavailability of ellagic acid (EA) and to explore the therapeutic potential of mEVs in neuroinflammation treatment, we encapsulated EA and interferon-β (IFN-β) into mEVs and evaluated their therapeutic effects in experimental autoimmune encephalomyelitis (EAE) and lipopolysaccharide-induced neuroinflammation models. The results showed that mEV@IFN-β and mEV@EA significantly relieved disease progression and improved neuroinflammation compared to free drugs, with enhanced stability and bioavailability. Overall, our study findings establish mEVs as an efficient oral delivery platform capable of overcoming biological barriers for treating neuroinflammatory diseases, with the chitosan-based isolation method offering a scalable production approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Medicinal Resources and Natural Pharmaceutical Chemistry (Shaanxi Normal University), The Ministry of Education; College of Life Sciences, Shaanxi Normal University, Xi'an, Shaanxi710119, China.
- Datong Key Laboratory of Smart Medicine and Health Care for Elderly Chronic Diseases, Shanxi Datong University School of Medicine, Datong, Shanxi037009, China.
- Department of Neurology, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi710119, China.
ORCID-Profile: Zhe-An Zhou, Yuan Zhang, Xing Li
Förderung
- Fundamental Research Funds for the Central Universities
- Shanxi Provincial Science and Technology Department
Zitieren
APA
Bao, M. Y., Li, Y. H., Zhou, Z. A., Zhang, L. J., Han, X. Y., Guo, X. Y., Guo, X. Y., Tian, M. Y., Hao, D. X., Zhang, W. F., Ding, X. L., Zhang, Y., & Li, X. (2026). Oral Milk-Derived Extracellular Vesicles: A Promising Drug Delivery System for Neuroinflammatory Diseases. ACS Biomaterials Science & Engineering. https://doi.org/10.1021/acsbiomaterials.6c00969
Vancouver
Bao MY, Li YH, Zhou ZA, Zhang LJ, Han XY, Guo XY, et al. Oral Milk-Derived Extracellular Vesicles: A Promising Drug Delivery System for Neuroinflammatory Diseases. ACS Biomaterials Science & Engineering. 2026. doi:10.1021/acsbiomaterials.6c00969
BibTeX
@article{Bao2026,
author = {Bao, Ming-Yue and Li, Yan-Hua and Zhou, Zhe-An and Zhang, Lin-Jie and Han, Xin-Yan and Guo, Xin-Ya and Guo, Xiao-Yan and Tian, Meng-Yuan and Hao, Dong-Xia and Zhang, Wei-Feng and Ding, Xiao-Li and Zhang, Yuan and Li, Xing},
title = {Oral Milk-Derived Extracellular Vesicles: A Promising Drug Delivery System for Neuroinflammatory Diseases},
journal = {ACS Biomaterials Science & Engineering},
year = {2026},
doi = {10.1021/acsbiomaterials.6c00969}
}
EUVIMED